Connect with us

BIOTECH

Biotech On Track To Develop Bio-Synthetic Cannabinoids

Published

on

InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) released news Sept 25, 2017 revealing that the company had made breakthroughs in the scale-up and commercialization of the biosynthesis process for cannabinoid production.

IN/IMLFF noted that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms.   InMed President, Eric Adams, explained that through synthesis, IN/IMLFF could produce a variety of cannabinoids economically, which opens the door for new products.

Adams further noted that InMed was “dedicating substantial resources” to the commercialization of biosynthetic cannabinoid products.

Financials Trend began covering InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) following its news on Sept 19, 2017, after announcing the filing of patents on biosynthesis of cannabinoids.  At the time we published that story, shares of InMed Pharmaceuticals rose 7% to $0.36.  Now, IN/IMLFF is trading at nearly $0.45.

We noted in our IN/IMLFF story that it was [BIG NEWS to the scientific community], but Mr. Adams clarified that further in yesterday’s press release when he explained how some extracts from marijuana are expensive to produce but through biosynthesis synthetic cannabinoids are just the opposite.

“The biosynthesis process opens up access to drug discovery and therapeutic use of all 90+ cannabinoids, most of which occur in only trace amounts in the plant and cannot be extracted in an economical fashion,” said Adams.

InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) shares are trading up over 100% since Financials Trend first covered the company.  In that first article, we called InMed Pharmaceutical a “Five Bagger”, noting its gateway price of $0.21 at the time IN/IMLFF announced its patent applications and so far, it’s not disappointing our readers.  Our outlook hasn’t changed, yet we still stress patience in following IN/IMLFF progress.

 

BIOTECH

Insys Therapeutics Inc (NASDAQ:INSY) Issues An Update on CBD Pharmaceuticals and Spray Technology Products

Published

on

By

Insys Therapeutics Inc (NASDAQ:INSY) has issued an update on the naloxone nasal and epinephrine sprays and CBD oral solutions. CEO and President of Insys Therapeutics, Saeed Motahari said the company is focusing on novel drug delivery systems and pharmaceutical grade cannabinoids to drive the growth going forward. It is moving away from opioids. The company is transforming its business strategy to include patient-centric formulations over the past one year. Going forward,  Insys Therapeutics is preparing to submit 6 innovative drug applications in the next 3 years. The company is scheduling two of them in 2019.

An update on the Opioid Related Assets

As per the announced plans,  Insys Therapeutics is scheduling the alternative review of the opioid related assets. As of now, nine firms have entered into a pact with  Insys Therapeutics and are reviewing the confidential information. The company will release an update on this aspect in early 2019.

An Update on the Lifesaving Products

Insys Therapeutics is in the advanced stages of developing the lifesaving investigational products that are based on spray technologies. Its lifesaving products in development include epinephrine nasal spray for anaphylaxis and naloxone nasal spray for the opioid overdose.

The company is also focusing on cannabinoids like CBD oral solution targeting the child absence epilepsy treatment (phase 2), Prader Willi Syndrome (phase 2), infantile spasms (phase 3), and dronabinol inhalation to treat a variety of conditions such as anorexia in patients suffering from cancer.

Insys Therapeutics is conducting a non-clinical toxicity study on naloxone nasal spray and expects to announce the results in March 2019. The company has set the timeframe for the NDA submission in Q1 2019.

Epinephrine nasal spray, which is intended for needle-free delivery, is a substitute to the intramuscular injection. According to the study, it is readily absorbed via the nasal mucosa. The company has obtained FDA nod for fast track designation for the drug in August 2018. It has also provided specific guidelines for filing requirement and clinical development. Insys Therapeutics is optimistic to complete the filing requirements for epinephrine NDA in Q4, 2019. It is subject to successful completion of PK study.

The company has successfully completed a proof of concept study on dronabinol inhalation in September 2018. Insys Therapeutics will arrange a meeting with clinical experts in Q1 2019 to discuss further development for this investigational formulation.

Insys Therapeutics Signs a Pact with Lunatus for Commercializing SUBSYS

Insys Therapeutics has signed a definitive accord with Lunatus for commercializing Subsys in 8 nations in the Middle East. Following the deal, Lunatus will act as an authorized agent and licensee in the UAE, Lebanon, Kuwait, Jordan, Saudi Arabia, Qatar, Oman, and Bahrain.

Continue Reading

BIOTECH

International Consolidated Inc (OTCMKTS:INCC) Pronounces A $5 Million Dollar Institutional Offer

Published

on

International Consolidated Inc (OTCMKTS:INCC) is quite pleased to make the announcement that obtained an institutional offer worth $5 million dollars from the IFG Opportunity Fund LLC. According to a person well conversant with the matter, it happened prior to the company becoming fully reporting.

The business guru is making plans to move ahead and execute its business plan and it is crucial to mention the point that the undertaking served them with about three 3 additional options for funding.

The company’s take on business operations

It was way back in 2004 that the IFG Opportunity Fund, LLC began as a private equity fund set up to make investments in the series of the small growth companies via the PIPE’s which are fundamentally private investments in public equities.

They invest in their own capital and that of course indicates more flexibility as well as a greater competitive advantage at a time when business dynamics tend to be shifting quite fast. Competitive pricing is a point that the business giant takes with much seriousness and market observers have termed that a great way to move about business.

The water-soluble CBD oil super food and expert strategies

The water-soluble CBD oil super food and wellness drinks that are being introduced by BluDog Products are easily absorbed. And they are the perfect alternative for over-the-counter therapeutic option that helps promote well being and relaxation.

Asides from that they play a significant role helping relieve post-sports inflammation not forgetting that the CBD products naturally interact with the anti-inflammatory system of the body and there are no associated side effects.

The Managing Member of BluDog Products LLC Antonio Uccello while moving out of a business conference addressed news reporters telling them that as a company they were quite pleased about getting to the point of providing high quality BluDog Products.

Much has been happening in the recent years, one of the things being the acquisition of the American Nutritional Products Inc. Several market analysts have said that the company is placing itself on the right path in the quest to achieve monumental success in a market characterized with stiff competition.

Continue Reading

BIOTECH

Premier Biomedical Inc (OTCMKTS:BIEI) Searches For Development Partner To Develop Patent Pending Technology

Published

on

Premier Biomedical Inc (OTCMKTS:BIEI) reported that they are actively looking for an associate to advance their patented extracorporeal treatment procedure in together with their patent pending process for treating ailments through the application of lasers.

The buzz

The methodology uses the concept of curing the blood outside the human body in a continuous flow procedure, together with an emissive energy means, such as a laser, to destroy directed antigens in the blood, before returning the blood to the person. The firm has exceptional privileges to three dispensed patents, one provisional patent application and six pending applications, all related to unique treatments for cancer as well as extracorporeal treatments for different life-threatening ailments.

Dr. Felder, the Inventor of the underlying technologies, expressed that the application of lasers in conjunction with their extracorporeal treatment procedure is a thrilling concept, as it should eliminate any infectious ailment, without the probability of pathogen resistance, or the action of side effects from the therapy. It also has the prospect for being an efficacious and inexpensive treatment for septicemia — a major cause of death globally.

William A. Hartman, the CEO and President of Premier Biomedical, expressed that they consider this combination of their patented extracorporeal treatment procedure with their patent awaiting emissive energy ablation of directed antigens could pave a complete new chapter in the means diseases are cured. The efficacy and safety of treatment protocols for a broad range of ailments could be considerably improved.

Premier Biomedical marks as a research-based publicly traded firm that plans to develop and discover medical treatments for a broad range of ailments in humans. The company has obtained, through different license agreements, the know-how behind three allowed US Patents, several pending provisional patents, as well as a ‘PCT’ Europe National Patent. Premier Biomedical was established back in 2010.

Continue Reading
Advertisement

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Trade


FEATURED STORIES

Business6 hours ago

First Foods Group Inc (OTCMKTS:FIFG) Unveils Its “Southeast Edibles” New Product Line

Post Views: 80 First Foods Group Inc (OTCMKTS:FIFG) today disclosed details about the unveiling of its latest product called “Southeast...

Business3 days ago

General Cannabis Corp (OTCMKTS:CANN) Plans To Acquire A Denver Vertically Integrated Cultivator And Retailer

Post Views: 211 General Cannabis Corp (OTCMKTS:CANN) is pleased to announce that it will soon make its latest acquisition. However,...

Business3 days ago

Leafbuyer Technologies Inc (OTCMKTS:LBUY) To Create A Mobile App With Blockchain Capabilities

Post Views: 464 Leafbuyer Technologies Inc (OTCMKTS:LBUY) today spoke at length regarding the development of a new mobile application. The...

Business4 days ago

Cannabis Science Inc (OTCMKTS:CBIS) Confirms The Success Of Its Reorganization Activities

Post Views: 291 Cannabis Science Inc (OTCMKTS:CBIS) has spoken in regards to its European business. The company outlines that its...

Business4 days ago

Agraflora Organics International Inc (OTCMKTS:AGFAF) And Eviana Strike A Beneficial Deal For Shareholders

Post Views: 234 Agraflora Organics International Inc (OTCMKTS:AGFAF) disclosed information regarding an offer it wants to make. If all goes...

BENEFITS OF CBD5 days ago

CBD and Endocrine Diseases

Post Views: 252 The endocrine system is a collection of glands all over the body that is responsible for the...

TRENDING5 days ago

CBD and Diabetes Treatment

Post Views: 395 CBD and Diabetes Treatment The hemp oil extracted from the cannabis plant is currently receiving good press...

Business5 days ago

ENDEXX ORD (OTCMKTS:EDXC) Targets 300 Stores Through Accelerated Growth Strategy

Post Views: 234 ENDEXX ORD (OTCMKTS:EDXC), also known as CBD Unlimited has announced the launch of an accelerated program that...

Business5 days ago

Medical Marijuana Inc (OTCMKTS:MJNA) Starts Producing Watermelon-Flavored CBD-Infused Gummies

Post Views: 193 Medical Marijuana Inc (OTCMKTS:MJNA) recently announced the launch of its watermelon-flavored CBD gummies, adding to its growing...

TRENDING6 days ago

CBD and Depression

Post Views: 387 Now that mental health is being given as much attention as physical health, it is becoming clearer...

Whats Hot

Create a future where the human body can repair, restore, and rejuvenate itself

 

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Play